LINAWISE-M-5/500

Linawise-M 5/500 (Linagliptin 5 mg + Metformin HCl 500 mg) is a combination therapy formulated with linagliptin 5 mg and metformin HCl 500 mg to help provide effective glycemic control in adults with type 2 diabetes mellitus. This advanced combination works through complementary mechanisms to help improve blood sugar levels while supporting overall metabolic health. It combines linagliptin, a DPP-4 inhibitor, with metformin hydrochloride, a widely trusted antihyperglycemic agent, to provide comprehensive blood glucose control. Linagliptin works by enhancing incretin hormone activity, which helps increase insulin secretion and reduce glucagon levels in a glucose-dependent manner. Metformin helps decrease hepatic glucose production and improves insulin sensitivity, leading to better glucose utilization by the body. This dual-action combination helps control both fasting and post-meal blood sugar levels and supports long-term glycemic management when used along with diet and exercise.

How does Linawise-M 5/500 (Linagliptin 5mg + Metformin HCl 500 mg) work ?

Linagliptin (5 mg) - DPP-4 Inhibitor:

• Inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which normally breaks down incretin hormones (GLP-1 and GIP).
• By increasing active incretin levels, linagliptin promotes insulin release from pancreatic \(\beta \)-cells in a glucose-dependent manner (only when blood sugar is high) and reduces glucagon release from \(\alpha \)-cells.
• Reduces post-prandial (after-meal) blood glucose spikes.

Metformin HCl (500 mg) - Biguanide:

• Primarily inhibits hepatic gluconeogenesis (the production of glucose in the liver) and improves peripheral insulin sensitivity.
• Enhances peripheral glucose uptake and utilization in muscles and increases intestinal GLP-1 production.
• Significantly reduces fasting plasma glucose levels. 

Clinical Benefits 

• Linagliptin (DPP-4 Inhibitor): Increases incretin hormones, which make the pancreas release more insulin only when required and lower glucagon levels.
• Metformin (Biguanide): Decreases glucose production in the liver, reduces intestinal glucose absorption, and improves insulin sensitivity.

Low Risk of Hypoglycemia: Unlike other combinations (e.g., with sulfonylureas), this combination is weight-neutral and carries a very low risk of causing dangerous hypoglycemia (very low blood sugar).

Renal/Hepatic Suitability: Linagliptin is primarily excreted through the bile, making this combination generally suitable for patients with mild to moderate renal (kidney) or hepatic (liver) impairment without the need for dose adjustments, unlike other DPP-4 inhibitors.

Improved Adherence: As a single-pill, twice-daily combination, it simplifies treatment, reduces pill burden, and improves patient compliance compared to taking medications separately.

Cardiovascular Safety: Studies have shown that linagliptin does not increase the risk of heart failure or major adverse cardiovascular events. 

Dosage & Administration

The Linawise-M 5/500 ( Linagliptin 5 mg + Metformin HCl 500 mg)

The tablet should be taken exactly as directed by the physician.
The dosage may vary depending on the patient’s medical condition, blood glucose levels, and response to treatment.
It is generally recommended to take the tablet with meals to minimize gastrointestinal discomfort associated with metformin.
Do not discontinue or alter the dosage without medical advice.

Disclaimer

The information provided herein is intended for educational and informational purposes only and should not be considered as medical advice. The Linawise-M 5/500 (Linagliptin 5 mg + Metformin HCl 500 mg)

Tablets should be used strictly under the supervision of a qualified healthcare professional. Please read the package insert carefully before use. Keep out of reach of children.